Plasma Ceramides Are Elevated in Obese Subjects with Type 2 Diabetes and Correlate with the Severity of Insulin Resistance

Overview

Journal Diabetes

Specialty Endocrinology

Date 2008 Nov 15

PMID 19008343

Citations 324

Authors

Jacob M Haus

Sangeeta R Kashyap

Takhar Kasumov

Renliang Zhang

Karen R Kelly

Ralph A DeFronzo

John P Kirwan

Affiliations

Soon will be listed here.

Abstract

Objective: To quantitate plasma ceramide subspecies concentrations in obese subjects with type 2 diabetes and relate these plasma levels to the severity of insulin resistance. Ceramides are a putative mediator of insulin resistance and lipotoxicity, and accumulation of ceramides within tissues in obese and diabetic subjects has been well described.

Research Design And Methods: We analyzed fasting plasma ceramide subspecies by quantitative tandem mass spectrometry in 13 obese type 2 diabetic patients and 14 lean healthy control subjects. Results were related to insulin sensitivity measured with the hyperinsulinemic-euglycemic clamp technique and with plasma tumor necrosis factor-alpha (TNF-alpha) levels, a marker of inflammation. Ceramide species (C18:1, 18:0, 20:0, 24:1, and 24:0) were quantified using electrospray ionization tandem mass spectrometry after separation with high-performance liquid chromatography.

Results: Insulin sensitivity (mg x kg(-1) x min(-1)) was lower in type 2 diabetic patients (4.90 +/- 0.3) versus control subjects (9.6 +/- 0.4) (P < 0.0001). Type 2 diabetic subjects had higher (P < 0.05) concentrations of C18:0, C20:0, C24:1, and total ceramide. Insulin sensitivity was inversely correlated with C18:0, C20:0, C24:1, C24:0, and total ceramide (all P < 0.01). Plasma TNF-alpha concentration was increased (P < 0.05) in type 2 diabetic subjects and correlated with increased C18:1 and C18:0 ceramide subspecies.

Conclusions: Plasma ceramide levels are elevated in type 2 diabetic subjects and may contribute to insulin resistance through activation of inflammatory mediators, such as TNF-alpha.

Citing Articles

The influence of circadian rhythm disruption during Ramadan on metabolic responses to physical activity: a pilot study.

Anwardeen N, Naja K, Almuraikhy S, Sellami M, Al-Amri H, Philip N Front Neurosci. 2025; 19:1542016.

PMID: 40066156 PMC: 11891360. DOI: 10.3389/fnins.2025.1542016.

Elevated Very-Long-Chain Ceramides in the Vitreous Humor of Patients With Proliferative Diabetic Retinopathy.

Chen Y, Yang C, Yang C, Ho T, Hsieh Y, Lai T Invest Ophthalmol Vis Sci. 2025; 66(2):28.

PMID: 39932474 PMC: 11817849. DOI: 10.1167/iovs.66.2.28.

A Mendelian randomization study on associations between plasma lipidome, circulating inflammatory proteins, and erectile dysfunction.

Yu J, Liang P Transl Androl Urol. 2025; 13(12):2724-2734.

PMID: 39816232 PMC: 11732301. DOI: 10.21037/tau-24-378.

Role of dietary and nutritional interventions in ceramide-associated diseases.

Wang S, Jin Z, Wu B, Morris A, Deng P J Lipid Res. 2024; 66(1):100726.

PMID: 39667580 PMC: 11754522. DOI: 10.1016/j.jlr.2024.100726.

Plasma C24:0 ceramide impairs adipose tissue remodeling and promotes liver steatosis and glucose imbalance in offspring of rats.

Camacho-Morales A, Noriega L, Sanchez-Garcia A, Torre-Villalvazo I, Vazquez-Manjarrez N, Maldonado-Ruiz R Heliyon. 2024; 10(20):e39206.

PMID: 39640709 PMC: 11620212. DOI: 10.1016/j.heliyon.2024.e39206.

References

Unger R . Minireview: weapons of lean body mass destruction: the role of ectopic lipids in the metabolic syndrome. Endocrinology. 2003; 144(12):5159-65. DOI: 10.1210/en.2003-0870. View

Skovbro M, Baranowski M, Skov-Jensen C, Flint A, Dela F, Gorski J . Human skeletal muscle ceramide content is not a major factor in muscle insulin sensitivity. Diabetologia. 2008; 51(7):1253-60. DOI: 10.1007/s00125-008-1014-z. View

Jackson A, Pollock M, Graves J, Mahar M . Reliability and validity of bioelectrical impedance in determining body composition. J Appl Physiol (1985). 1988; 64(2):529-34. DOI: 10.1152/jappl.1988.64.2.529. View

Koves T, Ussher J, Noland R, Slentz D, Mosedale M, Ilkayeva O . Mitochondrial overload and incomplete fatty acid oxidation contribute to skeletal muscle insulin resistance. Cell Metab. 2008; 7(1):45-56. DOI: 10.1016/j.cmet.2007.10.013. View

Wong M, Xie B, Beatini N, Phu P, Marathe S, Johns A . Acute systemic inflammation up-regulates secretory sphingomyelinase in vivo: a possible link between inflammatory cytokines and atherogenesis. Proc Natl Acad Sci U S A. 2000; 97(15):8681-6. PMC: 27008. DOI: 10.1073/pnas.150098097. View

Peraldi P, Hotamisligil G, Buurman W, White M, Spiegelman B . Tumor necrosis factor (TNF)-alpha inhibits insulin signaling through stimulation of the p55 TNF receptor and activation of sphingomyelinase. J Biol Chem. 1996; 271(22):13018-22. DOI: 10.1074/jbc.271.22.13018. View

Kirwan J, Hauguel-De Mouzon S, Lepercq J, Challier J, Huston-Presley L, Friedman J . TNF-alpha is a predictor of insulin resistance in human pregnancy. Diabetes. 2002; 51(7):2207-13. DOI: 10.2337/diabetes.51.7.2207. View

Goodpaster B, Kelley D . Skeletal muscle triglyceride: marker or mediator of obesity-induced insulin resistance in type 2 diabetes mellitus?. Curr Diab Rep. 2003; 2(3):216-22. DOI: 10.1007/s11892-002-0086-2. View

Wellen K, Hotamisligil G . Inflammation, stress, and diabetes. J Clin Invest. 2005; 115(5):1111-9. PMC: 1087185. DOI: 10.1172/JCI25102. View

10.

Lightle S, Oakley J, Nikolova-Karakashian M . Activation of sphingolipid turnover and chronic generation of ceramide and sphingosine in liver during aging. Mech Ageing Dev. 2000; 120(1-3):111-25. DOI: 10.1016/s0047-6374(00)00191-3. View

11.

Nelson J, Jiang X, Tabas I, Tall A, Shea S . Plasma sphingomyelin and subclinical atherosclerosis: findings from the multi-ethnic study of atherosclerosis. Am J Epidemiol. 2006; 163(10):903-12. DOI: 10.1093/aje/kwj140. View

12.

Ichi I, Nakahara K, Miyashita Y, Hidaka A, Kutsukake S, Inoue K . Association of ceramides in human plasma with risk factors of atherosclerosis. Lipids. 2006; 41(9):859-63. DOI: 10.1007/s11745-006-5041-6. View

13.

Hajduch E, Balendran A, Batty I, Litherland G, Blair A, Downes C . Ceramide impairs the insulin-dependent membrane recruitment of protein kinase B leading to a loss in downstream signalling in L6 skeletal muscle cells. Diabetologia. 2001; 44(2):173-83. DOI: 10.1007/s001250051596. View

14.

Quintern L, Zenk T, Sandhoff K . The urine from patients with peritonitis as a rich source for purifying human acid sphingomyelinase and other lysosomal enzymes. Biochim Biophys Acta. 1989; 1003(2):121-4. DOI: 10.1016/0005-2760(89)90244-0. View

15.

Holland W, Summers S . Sphingolipids, insulin resistance, and metabolic disease: new insights from in vivo manipulation of sphingolipid metabolism. Endocr Rev. 2008; 29(4):381-402. PMC: 2528849. DOI: 10.1210/er.2007-0025. View

16.

Prins J, Niesler C, Winterford C, Bright N, Siddle K, ORahilly S . Tumor necrosis factor-alpha induces apoptosis of human adipose cells. Diabetes. 1997; 46(12):1939-44. DOI: 10.2337/diab.46.12.1939. View

17.

Soeda S, Honda O, Shimeno H, NAGAMATSU A . Sphingomyelinase and cell-permeable ceramide analogs increase the release of plasminogen activator inhibitor-1 from cultured endothelial cells. Thromb Res. 1995; 80(6):509-18. DOI: 10.1016/0049-3848(95)00206-5. View

18.

Delogu G, Famularo G, Amati F, Signore L, Antonucci A, Trinchieri V . Ceramide concentrations in septic patients: a possible marker of multiple organ dysfunction syndrome. Crit Care Med. 1999; 27(11):2413-7. DOI: 10.1097/00003246-199911000-00015. View

19.

. Diagnosis and classification of diabetes mellitus. Diabetes Care. 2008; 31 Suppl 1:S55-60. DOI: 10.2337/dc08-S055. View

20.

Ichi I, Takashima Y, Adachi N, Nakahara K, Kamikawa C, Harada-Shiba M . Effects of dietary cholesterol on tissue ceramides and oxidation products of apolipoprotein B-100 in ApoE-deficient mice. Lipids. 2007; 42(10):893-900. DOI: 10.1007/s11745-007-3067-z. View